How Drug Pricing Works: List Price, Net Price and the Gross-to-Net Gap

rgultig

July 29, 2026

The most misunderstood number in healthcare finance—and how a drug can have a $1,000 list price and a $300 net price, paid by different buyers for the same pill.

Every prescription filled in America travels through a pricing system where the price visible to the customer is not the price anyone actually pays. A patient sees a list price at the pharmacy that the insurance never reimburses. A hospital buys the same drug at a 340B discount. An employer’s health plan negotiates a rebate. Medicare pays a different price under a different rule. And the manufacturer keeps track of all of them separately, calculating the “net price” that determines whether the product is profitable.

This report maps how that system works: how list prices are set, why the gap between list and net has grown to nearly half of total revenues, which buyer pays what, and what is changing in 2026.

The basics: List price is not a real price

List price — technically, the wholesale acquisition cost or WAC — is the published price that manufacturers post and wholesalers use as a reference point. For brand-name drugs, list prices have been rising at roughly 5-10% annually for years, compounding into headline-ready numbers: a drug that cost $100 per unit in 2015 might carry an $180-200 list price by 2026.

But almost no one pays the list price. Manufacturers offer rebates to insurance companies and pharmacy benefit managers. Government programs impose mandatory discounts. Employers negotiate rates. Pharmacies get contracted prices. And patients on coinsurance often pay a percentage of the list price, not the net price the system actually paid.

The result is what industry researchers call the “gross-to-net” gap: the difference between the published list price and the actual net price the manufacturer receives after all discounts, rebates and fees are accounted for. In 2024, that gap totaled roughly $356 billion to $416 billion across all brand-name drugs sold in the US market — more money than the entire annual budget of the National Institutes of Health.

How large is the gap?

Gross-to-net discounts for major brand-name drug portfolios average between 36% and 60%, meaning manufacturers frequently receive only 40-64% of the published list price. In practical terms, a drug with a $1,000 list price might be paid at a $400-640 net price depending on the buyer and the program.

The gap varies sharply by therapy class and competitive position. Highly competitive categories — oncology, immunology, cardiovascular — see deeper rebates as manufacturers compete for formulary placement. Off-patent drugs in crowded generics markets may see net prices that are single-digit percentages of their historical list price.

The 2024 GTN total of $356-416 billion represents a slowdown in the gap’s expansion. For years it grew faster than prescription drug spending itself, meaning the gap was widening. In 2025 and 2026, it is not — a signal that the bubble is deflating. Manufacturers have begun cutting list prices on certain drugs (25-85% cuts in some cases), a trend that was rare and shocking five years ago and is becoming more common. The traditional high-list-price/high-rebate model that dominated the past two decades is showing stress.

Where the gap comes from: The five layers of discount

1. PBM rebates (the largest component)

Pharmacy benefit managers — the middlemen between manufacturers and insurance plans — negotiate rebates in exchange for favorable formulary placement. A rebate is a retrospective payment: the manufacturer sets a list price, the PBM and insurer negotiate a rebate amount (often expressed as a percentage of list price), and at year-end, after the PBM can demonstrate that it delivered a certain volume of sales, the manufacturer pays the rebate back.

The three largest PBMs — CVS Caremark, Express Scripts (Cigna) and OptumRx — manage 79% of US prescription drug claims. This concentration gives them enormous negotiating power. They credibly threaten to exclude a drug from their formulary or place it on a high-cost-sharing tier unless the manufacturer agrees to a rebate. Exclusion is devastating for a brand-name drug because patients typically choose based on cost-sharing, not clinical superiority, and an exclusion can drop utilization by 80% or more.

Manufacturers accept these rebates because losing formulary access is worse than accepting one. The leverage is asymmetric: PBMs have thousands of drugs to choose from; manufacturers have one drug. PBMs have also grown increasingly sophisticated at squeezing: they can tier drugs (Tier 3 preferred brand $10 copay vs. Tier 4 non-preferred brand $80 copay), exclude drugs, or limit them to specialty pharmacies. Each tactic forces manufacturers into rebate negotiations.

As a result, PBM rebates typically account for the largest component of the gap — often 20-40 percentage points off the list price, depending on the drug.

2. Medicaid rebates (mandatory minimum)

Medicaid law requires manufacturers to offer a “best price” rebate tied to the average manufacturer price (AMP). The formula is complex, but the effect is simple: Medicaid (and any other government or private payer) can demand a rebate equal to a sliding scale based on list price changes, forcing manufacturers to keep list prices down or face automatic Medicaid rebate increases.

This creates a perverse incentive: raising list prices to increase the rebate base for commercial deals also increases the Medicaid rebate obligation automatically. For certain drugs, Medicaid represents a quarter or more of the patient population, so the rebate is material.

3. 340B program discounts

The 340B Drug Pricing Program requires manufacturers selling to Medicaid to also offer discounts to “covered entities” — hospitals, clinics, and safety-net providers serving uninsured and underinsured patients. The 340B ceiling price is typically 23-50% below the average manufacturer price, depending on the drug.

Hospitals can buy drugs at the 340B price, then resell them to patients, pocketing the savings. This is legal and programmatic — hospitals use 340B margins to fund uncompensated care. But it also means manufacturers receive yet another discounted price on the same drug, to yet another buyer class.

As of 2024, covered entities purchased $81.4 billion of drugs at 340B prices. A federal court vacated a proposed “340B rebate model pilot” in February 2026 that would have shifted the program from upfront discounts to retrospective rebates, so the program continues to operate as an upfront discount system as of mid-2026.

4. Patient assistance programs and copay cards

Manufacturers offer copay assistance cards (sometimes called copay coupons or manufacturer savings cards) to help commercially insured patients afford out-of-pocket costs. A patient might face a $200 copay on a specialty drug; a manufacturer copay card might reduce that to $10 or $0 for a year.

These copay cards are a form of discount to the patient, not the insurance company, but they affect net revenues. And increasingly, insurance plans use “copay accumulator” or “copay maximizer” programs that prevent manufacturer assistance from counting toward the patient’s annual out-of-pocket maximum — meaning the manufacturer is paying the patient to reduce their out-of-pocket cost, but that discount doesn’t reduce the total the patient owes the insurer. As of 2026, roughly 40% of ACA marketplace plans use copay accumulator programs.

5. Government pricing programs (the newest wedge)

The Inflation Reduction Act of 2022 introduced a Medicare Drug Price Negotiation Program where Medicare can negotiate maximum fair prices (MFPs) for certain drugs, effective 2026. The first cohort includes 10 drugs, expanding over time. Manufacturers must charge covered entities (hospitals and clinics) the lower of the 340B price or the MFP.

This created a new coordination problem: is a covered entity covered by a 340B discount, an MFP, both, or neither? The program continues to evolve. As of mid-2026, the legal environment around how these programs interact is in flux.

Who pays what: The channel-specific pricing problem

The same drug has different net prices for different buyers because each channel operates under different rules.

Commercial insurance (employer plans, ACA marketplace): Patients typically see a copay (e.g., $10, $50, $100) or coinsurance (e.g., 25% of list price), depending on formulary tier. The insurance company negotiates a rebate with the manufacturer. The drug’s position on the formulary determines the patient’s cost-sharing and therefore utilization.

A patient on coinsurance pays based on list price, not net price. If the list price is $1,000, the drug’s net price is $400 (after a 60% rebate), and the patient’s coinsurance is 25%, the patient pays $250 (25% of $1,000), even though the system only paid $400 total.

Medicare Part D (senior prescription drug coverage): Similar structure to commercial — copays or coinsurance — but with added complexity. Patients on deductibles pay full price. Once in the coverage gap, they pay coinsurance. Medicare negotiated maximum fair prices began in 2026 for 10 drugs. Manufacturers can’t charge Part D enrollees more than the MFP, but can charge Part B (for intravenous drugs) at the MFP minus a required rebate.

Medicaid (state programs for low-income patients): Medicaid pays a rebated price set by law. States also negotiate supplemental rebates. Patients typically pay small copays. The economics of Medicaid are margin-compressed for manufacturers because the rebate is mandated and often doubled by state supplements.

Hospitals (340B program): Hospitals buy at the 340B ceiling price (a steep discount), then dispense to inpatients at no separate charge and outpatients at facility rates. Hospitals can also buy through their group purchasing organization (GPO), which negotiates member hospital rates — typically discounted but not as deeply as 340B.

Cash-pay patients (uninsured): No insurance means no rebate, no formulary, no negotiated price. Cash-pay patients typically face list price or a discount negotiated directly with the pharmacy (which might apply a percentage off list). Manufacturers increasingly run discount programs and “patient assistance” initiatives to prevent cash-pay patients from being priced out entirely. The TrumpRx initiative, announced in 2025 and operational in 2026, connects cash-pay patients with manufacturer coupons.

The list price is written backwards

Here is the mechanism that makes the system so confusing: manufacturers set list price first, knowing it will be discounted, and then work backward to the net price they actually want.

A manufacturer launching a new cancer drug might decide “we need a net price of $15,000 per monthly dose to support development and marketing.” They project that the drug will face 50% gross-to-net discounting in the market (based on similar drugs). So they set the list price at $30,000. The gap is not the result of an honest price negotiation — it is the intended outcome.

When list-price growth accelerates, the gap grows. The manufacturer can raise both list price and net price (by raising the rebate base) while the customer experiences a rising total cost hidden behind confidential rebate contracts. And because patient coinsurance is based on list price, a rising list price raises patient cost-sharing even if the actual system price (net price) is flat.

This is why transparency advocates focus on net price. List price is a fiction, negotiated in reverse. Net price is what actually gets paid.

The bubble is deflating, slowly

For 15 years, the GTN gap expanded faster than prescription drug spending. Manufacturers could raise list prices 8-10% annually, negotiate rebates that grew slower (maybe 5-6% annually), and pocket the difference. The gap compounded. Rebate complexity exploded. Whole companies (PBMs, pharmacy networks, copay assistance administrators) grew around managing the gap.

In 2025 and 2026, that model is breaking. Multiple pressures are simultaneous:

Federal pricing reforms. The IRA created the Medicare Drug Price Negotiation Program. The FTC has been scrutinizing PBM rebate practices and vertical integration. The Consolidated Appropriations Act of 2026 expanded the definition of what counts as a PBM to close loopholes where rebates were funneled to nominally separate entities.

Manufacturer list-price reductions. In 2024 and 2025, major manufacturers began cutting list prices on certain drugs by 25-85% — something that would have been unthinkable five years earlier. Manufacturers are experimenting with lower list prices and smaller gaps, betting that transparency and reduced controversy are worth the reduced rebate base.

Biosimilar and generic competition. As patents expire on blockbuster biologics, biosimilars and authorized generics are entering with list prices 20-40% below the reference product, compressing the rebate base for everyone.

Direct-to-patient distribution. Some manufacturers are experimenting with direct-to-patient pricing, cutting out middlemen and setting “net price” directly. These are niche experiments today but signal where the long-term pressure points are.

What this means for buyers

Net price is the number that matters for your costs. List price is a negotiating anchor and a public relations statement. It is not what you will pay. If you are building a financial model or doing competitive analysis, use net price, which you will need to either negotiate transparency on or infer from public disclosures, investor presentations, or regulatory filings.

Coinsurance exposes you to list-price risk. If your plan design uses coinsurance, a manufacturer’s list-price increase directly increases your cost-sharing, even if the payer negotiates a better rebate. Shifting patient cost-sharing from copays to coinsurance has become standard, and it means patients are bearing list-price risk while payers capture rebate gains.

Rebates may not show up in your spend reporting. Many employers and health plans don’t get real-time visibility into rebate flows. Rebates are reconciled at year-end, sometimes with months of lag. If you’re doing month-to-month budget tracking, you may see higher costs than you will actually owe once rebates settle.

The MFP is reshaping how expensive drugs are priced. Manufacturers of Medicare-eligible drugs are modeling around the MFP, not just the list price. If your organization covers Medicare patients, the MFP matters. Conversely, if you’re a manufacturer or vendor, the MFP is compressing margins on drugs in the negotiated cohort.

Transparency is improving, slowly. Federal and state regulations increasingly require PBMs to disclose rebate amounts, formulary criteria, and clinical reasoning. This data is starting to be public. Track it — it is shifting buyer leverage.

Frequently asked questions

What is a WAC (wholesale acquisition cost)?

WAC is the technical term for list price — the published price manufacturers charge wholesalers. It is the baseline against which rebates are calculated. Virtually no one pays WAC; it is an accounting reference, not a market price.

How do manufacturers decide what rebate to offer?

Manufacturers model the trade-off between volume (which rises with a lower cost-sharing tier) and margin (which falls with a higher rebate). They also have to account for Medicaid’s mandatory rebate formula, which ties their rebate obligation to their list price. Setting too high a list price triggers automatic Medicaid rebate increases. The math is complex and often done with confidential modeling that only the manufacturer and the PBM see.

Why can’t patients just see the net price at the pharmacy?

Rebates are confidential contracts between manufacturers and PBMs. Pharmacies don’t see them. Patients see a list price and their copay/coinsurance, which might both be based on the list price. The net price — the amount the system actually paid — is buried in insurance claim data that patients typically don’t access. Transparency on this has been a policy priority because of this opacity.

How does the 340B program work for patient costs?

Hospitals can buy drugs at a 340B price (steep discount). Inpatients get the drugs as part of their hospital bill, so they don’t see a separate copay. Outpatients buying the drug at a hospital outpatient pharmacy pay the facility’s price, which is typically higher than 340B but lower than retail. Patients at retail pharmacies have no access to 340B pricing.

Are copay cards and patient assistance the same thing?

No. Copay cards are for commercially insured patients and reduce the patient’s out-of-pocket cost but don’t help the uninsured. Patient assistance programs are for the uninsured and low-income (based on income verification) and provide free or reduced-cost medication. Copay accumulators can also prevent copay cards from counting toward deductibles/out-of-pocket maximums, which patients often don’t realize.

What is an “MFP” and how does it affect drug prices?

MFP is the Medicare maximum fair price set under the Inflation Reduction Act. For covered drugs, manufacturers can’t charge Medicare (or other buyers) more than the MFP. The program started in 2026 with 10 drugs and will expand. Manufacturers are modeling the MFP as a ceiling and pricing around it, which is compressing net prices for those drugs.

Sources

Post Views: 9

API Supply Chain: Where the World’s Drugs Are Made

Biologics vs Small Molecules: What the Cost and Supply Differences Mean